Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 6/20 | 0.50 |
| ▸ | AXL | P30530 | 2/20 | 0.50 |
| ▸ | IDO1 | P14902 | 3/20 | 0.43 |
| ▸ | METAP2 | P50579 | 4/20 | 0.41 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.41 |
| ▸ | TDO2 | P48775 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 3/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 2/20 | 0.36 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.36 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.36 |
| ▸ | FLT3 | P36888 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29428710 | 1.00 | NOS1 (0.50) | NOS1AXLIDO1METAP2CSNK2A1 | |
| Hydrochloric Acid SCHEMBL28520759 | 0.98 | NOS1 (0.48) | NOS1AXLIDO1METAP2CSNK2A1 | |
| SCHEMBL8404436 | 0.79 | IDO1 (0.46) | NOS1AXLIDO1METAP2ESR1 | |
| SCHEMBL21196238 | 0.78 | IDO1 (0.48) | NOS1AXLIDO1METAP2CSNK2A1 | |
| SCHEMBL5413400 | 0.76 | NOS1 (0.50) | NOS1AXLIDO1METAP2CSNK2A1 | |
| SCHEMBL2005907 | 0.76 | NOS1 (0.55) | NOS1AXLIDO1METAP2CSNK2A1 | |
| SCHEMBL5929682 | 0.76 | IDO1 (0.52) | NOS1AXLIDO1METAP2CSNK2A1 | |
| SCHEMBL767506 | 0.76 | NOS1 (0.55) | NOS1AXLIDO1METAP2CSNK2A1 | |
| SCHEMBL30959690 | 0.76 | NOS1 (0.55) | NOS1AXLIDO1METAP2CSNK2A1 | |
| SCHEMBL29493856 | 0.76 | NOS1 (0.50) | NOS1AXLIDO1METAP2CSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112321510-A | Preparation method of 4-bromo-5-methyl-1H-indazole | 无锡双启科技有限公司 | 2021-02-05 | — | — | CN | claimed |
| CN-122010905-A | Pyrazolyl derivatives as anticancer agents | 诺华股份有限公司 | 2026-05-12 | — | — | CN | disclosed |
| EP-4216951-B1 | KRAS G12D INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2026-04-01 | — | — | EP | disclosed |
| US-20260060961-A1 | SUBSTITUTED HETEROCYCLES AS RAS INHIBITORS | JAZZ PHARMACEUTICALS IRELAND LTD (IE) | 2026-03-05 | — | — | US | disclosed |
| EP-4344702-B1 | PYRAZOLYL DERIVATIVES USEFUL AS ANTI-CANCER AGENTS | NOVARTIS AG (CH) | 2026-01-28 | — | — | EP | disclosed |
| US-12435090-B2 | Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use | REPARE THERAPEUTICS INC. (CA) | 2025-10-07 | — | — | US | disclosed |
| WO-2025111513-A1 | COMPOUNDS USEFUL IN THE MODULATION OF KLHDC1 AND KLHDC2 ACTIVITY | NURIX THERAPEUTICS, INC. (US) | 2025-05-30 | — | — | WO | disclosed |
| WO-2025092989-A1 | SUBSTITUTED QUINAZOLINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMBINATION THEREOF, AND USE THEREOF | 泰州红云制药有限公司 | 2025-05-08 | — | — | WO | disclosed |
| WO-2025078984-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AS KRAS DEGRADERS | AURIGENE ONCOLOGY LIMITED (IN) | 2025-04-17 | — | — | WO | disclosed |
| WO-2025053850-A1 | COVALENT KRAS-BINDING COMPOUNDS FOR MEDICAL TREATMENT | HYKU BIOSCIENCES INC. (US) | 2025-03-13 | — | — | WO | disclosed |
| WO-2017201161-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2017-11-23 | — | — | WO | disclosed |
| EP-3159335-A2 | NOVEL HETEROCYCLIC COMPOUND | Daewoong Pharmaceutical Co., Ltd. (KR) | 2017-04-26 | — | — | EP | disclosed |
| US-20170088551-A1 | NOVEL HETEROCYCLIC COMPOUND | Daewoong Pharmaceutical., Ltd. (KR) | 2017-03-30 | — | — | US | disclosed |
| US-8586566-B2 | Unsaturated heterocyclic derivatives | ARIAD PHARMACEUTICALS, INC. (US) | 2013-11-19 | — | — | US | disclosed |
| US-20120178716-A1 | Unsaturated Heterocyclic Derivatives | ARIAD PHARMACEUTICALS, INC. (US) | 2012-07-12 | — | — | US | disclosed |
| US-8071609-B2 | Unsaturated heterocyclic derivatives | ARIAD PHARMACEUTICALS, INC. (US) | 2011-12-06 | — | — | US | disclosed |
| EP-2266983-A1 | NITROGENATED 5-MEMBERED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-12-29 | — | — | EP | disclosed |
| US-20090156596-A1 | Unsaturated Heterocyclic Derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| EP-1940843-A2 | UNSATURATED HETEROCYCLIC DERIVATIVES | ARIAD PHARMACEUTICALS, INC. (US) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007021937-A2 | UNSATURATED HETEROCYCLIC DERIVATIVES | ARIAD PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156596-A1 | Unsaturated Heterocyclic Derivatives | CYP2F1, CYP2J2, ALOX5 | NOS1 1772/4885AXL 4017/4885IDO1 2051/4885 |
| US-20260060961-A1 | SUBSTITUTED HETEROCYCLES AS RAS INHIBITORS | KRAS, NRAS, HRAS | NOS1 3015/4885AXL 678/4885IDO1 4151/4885 |
| US-20120178716-A1 | Unsaturated Heterocyclic Derivatives | CYP2F1, CYP2J2, ALOX5 | NOS1 1772/4885AXL 4017/4885IDO1 2051/4885 |
| US-12435090-B2 | Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use | PLK1, CSNK1A1, CSNK1G1 | NOS1 2399/4885AXL 1425/4885IDO1 2245/4885 |
| US-20170088551-A1 | NOVEL HETEROCYCLIC COMPOUND | AARS1, TARBP1, NSUN3 | NOS1 1598/4885AXL 4840/4885IDO1 4017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.